2-[2-[2-(5-Methyl-2-phenyl-1,3-oxazol-4-yl)ethylamino]acetyl]pyrrolidine-2-carbonitrile

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-[2-[2-(5-Methyl-2-phenyl-1,3-oxazol-4-yl)ethylamino]acetyl]pyrrolidine-2-carbonitrile
• 英文别名: 2-[2-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethylamino]acetyl]pyrrolidine-2-carbonitrile
• 化学式: C₁₉H₂₂N₄O₂
• 分子量: 338.4
• InChiKey: JWRFTFFNFNQGNU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  25
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  91
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• [EN] MODULATORS OF GPR119 AND THE TREATMENT OF DISORDERS RELATED THERETO<br/>[FR] MODULATEURS DE GPR119 ET TRAITEMENT DE TROUBLES ASSOCIÉS À CEUX-CI
  申请人：ARENA PHARM INC

  公开号：WO2014074668A1

  公开（公告）日：2014-05-15

  The present invention relates to compounds of Formula (I) and pharmaceutically acceptable salts, solvates, and hydrates thereof, Formula (I), that are useful as single pharmaceutical agents or in combination with one or more additional pharmaceutical agents, such as, an inhibitor of DPP-IV, a biguanide, an alpha-glucosidase inhibitor, an insulin analogue, a sulfonylurea, an SGLT2 inhibitor, a meglitinide, a thiazolidinedione, an anti-diabetic peptide analogue, or a DGAT-1 inhibitor, in the treatment of, for example, a disorder selected from: a GPR119-related disorder; a condition ameliorated by increasing secretion of an incretin; a condition ameliorated by increasing a blood incretin level; a condition characterized by low bone mass; a neurological disorder; a metabolic-related disorder; type 2 diabetes; obesity; and complications related thereto.

  本发明涉及化合物的公式(I)及其药学上可接受的盐、溶剂化合物和水合物，公式(I)可作为单一药物代理或与一个或多个其他药物代理结合使用，例如DPP-IV抑制剂、双胍类药物、α-葡萄糖苷酶抑制剂、胰岛素类似物、磺脲类药物、SGLT2抑制剂、胰岛素分泌促进剂、噻唑烷二酮类药物、抗糖尿病肽类似物或DGAT-1抑制剂，用于治疗例如GPR119相关疾病；通过增加内分泌物分泌改善的疾病；通过增加血液内分泌物水平改善的疾病；低骨量疾病；神经系统疾病；与代谢相关的疾病；2型糖尿病；肥胖及相关并发症。